• Summit Therapeutics Co-Chief Executive Officer Robert W. Duggan bought 3.81 million common shares at $13.12 each.
• Direct stake rose to 573,883,879 common shares following the purchase.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001055919-26-000007), on June 12, 2026, and is solely responsible for the information contained therein.